Overview

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Treatments:
Eptifibatide
Plasminogen
Tissue Plasminogen Activator